Search details
1.
Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV.
N Engl J Med
; 385(4): 330-341, 2021 07 22.
Article
in English
| MEDLINE | ID: mdl-34289276
2.
Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial.
Clin Infect Dis
; 68(7): 1184-1192, 2019 03 19.
Article
in English
| MEDLINE | ID: mdl-30060027
3.
Assessment of second-line antiretroviral regimens for HIV therapy in Africa.
N Engl J Med
; 371(3): 234-47, 2014 Jul 17.
Article
in English
| MEDLINE | ID: mdl-25014688
4.
Imatinib mesylate in the treatment of diffuse cutaneous mastocytosis.
J Pediatr
; 162(1): 205-7, 2013 Jan.
Article
in English
| MEDLINE | ID: mdl-23069194
5.
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.
Lancet HIV
; 9(6): e381-e393, 2022 06.
Article
in English
| MEDLINE | ID: mdl-35460601
6.
A hospital-based intermittent nocturnal hemodialysis program for children and adolescents.
J Pediatr
; 158(1): 95-9, 99.e1, 2011 Jan.
Article
in English
| MEDLINE | ID: mdl-20691454
7.
Quantifying HIV transmission flow between high-prevalence hotspots and surrounding communities: a population-based study in Rakai, Uganda.
Lancet HIV
; 7(3): e173-e183, 2020 03.
Article
in English
| MEDLINE | ID: mdl-31953184
8.
Inferring HIV-1 transmission networks and sources of epidemic spread in Africa with deep-sequence phylogenetic analysis.
Nat Commun
; 10(1): 1411, 2019 03 29.
Article
in English
| MEDLINE | ID: mdl-30926780
9.
Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial.
Lancet Infect Dis
; 18(1): 47-57, 2018 01.
Article
in English
| MEDLINE | ID: mdl-29108797
10.
HIV-1 viral load and resistance in genital secretions in patients taking protease-inhibitor-based second-line therapy in Africa.
Antivir Ther
; 23(2): 191-195, 2018.
Article
in English
| MEDLINE | ID: mdl-29021409
11.
Ethical considerations in global HIV phylogenetic research.
Lancet HIV
; 5(11): e656-e666, 2018 11.
Article
in English
| MEDLINE | ID: mdl-30174214
12.
HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa.
J Acquir Immune Defic Syndr
; 75(2): e45-e54, 2017 06 01.
Article
in English
| MEDLINE | ID: mdl-28129253
13.
Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.
Lancet HIV
; 4(8): e341-e348, 2017 08.
Article
in English
| MEDLINE | ID: mdl-28495562
14.
Neurocognitive Function at the First-Line Failure and on the Second-Line Antiretroviral Therapy in Africa: Analyses From the EARNEST Trial.
J Acquir Immune Defic Syndr
; 71(5): 506-13, 2016 Apr 15.
Article
in English
| MEDLINE | ID: mdl-26579985
15.
Interstitial 12p deletion involving more than 40 genes in a patient with postnatal microcephaly, psychomotor delay, optic nerve atrophy, and facial dysmorphism.
Meta Gene
; 2: 72-82, 2014 Dec.
Article
in English
| MEDLINE | ID: mdl-25606391
16.
Interaction of the adenovirus type 5 E4 Orf3 protein with promyelocytic leukemia protein isoform II is required for ND10 disruption.
J Virol
; 80(6): 3042-9, 2006 Mar.
Article
in English
| MEDLINE | ID: mdl-16501113
Results
1 -
16
de 16
1
Next >
>>